Charles A. Deignan, Chief Financial Officer at Clearside Biomedical, Inc. (CLSD), bought 7,500 shares at $1.14 ($9K) on 2019-11-12, disclosed to the SEC on 2019-11-13.
Open-market purchase of $9k CLSD by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| CLSD | SELL | 2022-01-20 | $18K | — | Filing → |
| CLSD | SELL | 2021-09-23 | $18K | — | Filing → |
| CLSD | SELL | 2021-06-23 | $13K | — | Filing → |